Fluoroquinolones showed no excess neuropathy against cephalosporins, and midlife epilepsy flags young-onset dementia

The edition in brief

Two UK primary-care cohorts of almost 3.9 million adults without diabetes found no association between fluoroquinolones and peripheral neuropathy within 60 days compared with cephalosporins (pooled aHR 0.96, 95% CI 0.77–1.20 at first prescription). The same method detected the known tendon rupture risk (aHR 1.98), which supports the analysis. Nationwide French and Swedish data linked epilepsy with young-onset dementia: adults with new epilepsy in midlife had a 10-year dementia incidence of 2.20% versus 0.21% without epilepsy (aHR 6.02). In 294 people with mild-to-moderate Parkinson disease followed for up to seven years, more total physical activity was associated with slower cognitive and motor decline; duration and ongoing activity mattered more than intensity. A Spanish referral-centre cohort applying a new consensus definition found nearly one in five people with generalised myasthenia gravis never reached adequate control over eight years, with no feature predicting who. The pearl covers fluoroquinolones and myasthenia.